[go: up one dir, main page]

ES2155834T3 - Procedimiento de tratamiento de lesiones o de disminuciones celulares. - Google Patents

Procedimiento de tratamiento de lesiones o de disminuciones celulares.

Info

Publication number
ES2155834T3
ES2155834T3 ES93920456T ES93920456T ES2155834T3 ES 2155834 T3 ES2155834 T3 ES 2155834T3 ES 93920456 T ES93920456 T ES 93920456T ES 93920456 T ES93920456 T ES 93920456T ES 2155834 T3 ES2155834 T3 ES 2155834T3
Authority
ES
Spain
Prior art keywords
injuries
cellular
decreases
procedure
processing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93920456T
Other languages
English (en)
Inventor
David A Williams
Steven C Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of ES2155834T3 publication Critical patent/ES2155834T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Dicing (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO DE RESTAURACION DE POBLACIONES DE CELULAS LESIONADAS O DEPLECIONADAS MEDIANTE EL TRATAMIENTO DEL PACIENTE CON CITOQUINAS, PARTICULARMENTE IL-11 Y IL-6.
ES93920456T 1992-09-02 1993-09-01 Procedimiento de tratamiento de lesiones o de disminuciones celulares. Expired - Lifetime ES2155834T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/941,372 US5460810A (en) 1992-09-02 1992-09-02 Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11

Publications (1)

Publication Number Publication Date
ES2155834T3 true ES2155834T3 (es) 2001-06-01

Family

ID=25476360

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93920456T Expired - Lifetime ES2155834T3 (es) 1992-09-02 1993-09-01 Procedimiento de tratamiento de lesiones o de disminuciones celulares.

Country Status (11)

Country Link
US (2) US5460810A (es)
EP (1) EP0671934B1 (es)
JP (1) JP2828778B2 (es)
AT (1) ATE198158T1 (es)
CA (1) CA2142879C (es)
DE (1) DE69329779T2 (es)
DK (1) DK0671934T3 (es)
ES (1) ES2155834T3 (es)
GR (1) GR3035413T3 (es)
PT (1) PT671934E (es)
WO (1) WO1994005318A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US5601814A (en) * 1994-08-05 1997-02-11 Schering Corporation Use of IL-6 to treat toxic shock
WO1996034620A1 (en) * 1995-05-05 1996-11-07 Schering Corporation Restoration of progenitor cells after antiproliferative therapy treatments
US5760189A (en) * 1995-06-02 1998-06-02 Genetics Institute, Inc. Protein recovery & purification methods
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5863529A (en) * 1995-09-20 1999-01-26 Mayo Foundation For Medical Education And Research Suppression of demyelination by interleukin-6
US5814308A (en) * 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
AU4669097A (en) * 1996-10-25 1998-05-22 Bristol-Myers Squibb Company Oncostatin m for treating inflammation
AUPO439396A0 (en) * 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
JP2003505429A (ja) * 1999-04-15 2003-02-12 ジェネティックス インスティテュート インコーポレイテッド 胃腸管障害を処置するためのインターロイキン−１１の使用
AU5328800A (en) * 1999-06-08 2000-12-28 Genetics Institute Inc. Use of interleukin-11 to treat hemorrhagic shock
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
JP5664623B2 (ja) * 2012-09-26 2015-02-04 東レ株式会社 改質されたインターロイキン−１１とその製造方法
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US20220096602A1 (en) * 2019-02-27 2022-03-31 Rutgers, The State University Of New Jersey Lif therapy for inducing intestinal epithelial cell regeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5214066A (en) * 1990-04-18 1993-05-25 Brigham And Women's Hospital Method for producing an animal model for inflammatory bowel disease including ulcerative colitis
ATE173763T1 (de) * 1991-08-30 1998-12-15 Hutchinson Fred Cancer Res Hybride cytokine

Also Published As

Publication number Publication date
CA2142879C (en) 2000-10-31
EP0671934B1 (en) 2000-12-20
EP0671934A4 (en) 1996-10-16
DE69329779D1 (de) 2001-01-25
PT671934E (pt) 2001-05-31
AU677236B2 (en) 1997-04-17
JP2828778B2 (ja) 1998-11-25
WO1994005318A1 (en) 1994-03-17
DK0671934T3 (da) 2001-02-26
US5460810A (en) 1995-10-24
JPH08500838A (ja) 1996-01-30
DE69329779T2 (de) 2001-08-09
AU5099993A (en) 1994-03-29
ATE198158T1 (de) 2001-01-15
GR3035413T3 (en) 2001-05-31
US5437863A (en) 1995-08-01
EP0671934A1 (en) 1995-09-20

Similar Documents

Publication Publication Date Title
ES2155834T3 (es) Procedimiento de tratamiento de lesiones o de disminuciones celulares.
ES2038756T3 (es) Dihidrato de azitromicina.
DE68904598D1 (de) Abwasserbehandlungsverfahren.
ES8306709A1 (es) Un procedimiento para la preparacion de 1,2-diamino clobuten-3,4-dionas.
DE3382387D1 (de) Loesungen von aminosaeuren zur parenteralen naehrung sowie dosierverfahren und verwendung.
NO167500C (no) Fremgangsmaate for ekstruderings-, transport- og kuttesystem.
MX9203319A (es) Metodo para la preparacion de cristales de alfa-2 interferona.
BG43856A3 (en) Method for protection from photozoas
DK422589A (da) Farmaceutisk praeparat til behandling af immundefekttilstande
DK67683D0 (da) Fremgangsmade til fremstilling af 2,3-diaryl-5-halogen-thio-phener
EG18865A (en) Phenoxypenythioureas, phenoxyphenylisothiourreas and phenoxyphenylcarbodiimides and use thereof for controlling pests.
NO881510D0 (no) Sterilt formeringssystem.
DE69228665D1 (de) Eukaryotisches Expressionssystem
IT1237088B (it) N,n'-di-(trimetossibenzoil) piperazine 2-carbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
MY129918A (en) Method for treating hypertension.
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
ZA876072B (en) Protein protease inhibitors from streptomyces
DK435089A (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
EP0548376A4 (es)
EP0172917A4 (en) AGENCIES FOR TREATING IMMUNODEFICIENCY, THEIR TREATMENT METHODS AND THE USE THEREOF.
ES2001249A6 (es) Un procedimiento para la preparacion de n-(2,6-difluorobenzoil)-n'-3,5-dicloro-4-n3,3,3-trifluoro-2-cloroprop-1-en-1-ilnfenil-urea con actividad insecticida
JPS57123160A (en) Phenyl-n-(cyanoalkylsulfenyl)-n-methylcarbamate, manufacture and noxious organism repellent
ES1021012Y (es) Mesa perfeccionada.
IT8221184V0 (it) Dispositivo di respirazione, per persone laringotomizzate.
UA19109A (uk) Спосіб посилеhhя протилейкозhої активhості циклофосфаhу

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671934

Country of ref document: ES